Abstract
In the conventional oncologic approach, patients with the same type of cancer are treated with similar drugs. However, clinical data often show that treatments may work well for some patients and not for others. This is because each patient has a unique profile, which results in different responses to the reference treatments. The use of patient-derived tumor organoids (PDOs) as predictiv…